Clinical case of methotrexate overdose, the peculiarity of diagnostics in the conditions of the COVID-19 pandemic
https://doi.org/10.30629/0023-2149-2023-101-4-5-241-246
Abstract
The diversity and low specifi city of clinical manifestations of COVID-19, as well as its widespread prevalence, present diffi culties for diff erential diagnosis, including conditions caused by drug overdose. The challenging experience of providing medical care during the coronavirus pandemic draws attention to the importance and necessity of further improving its diagnosis, especially in comorbid conditions. A clinical case of diff erential diagnosis of non- iatrogenic overdose of methotrexate in a patient with a preliminary diagnosis (virus unknown) is described: U07.2 (ICD-10) COVID-19.
About the Authors
I. V. Zaborskikh
City Hospital No. 2 of Miass Multidisciplinary Medical Center “Severny”
Russian Federation
Russian Federation
Zaborskikh Irina V.
456304, Miass
V. B. Simonenko
Military Medical Academy named after S.M. Kirov (Moscow branch) of the Ministry of Defense of Russia
Russian Federation
Russian Federation
Simonenko Vladimir B.
107392, Moscow
S. Kh. Sarmanaev
Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency; Academy of Postgraduate Education of the Federal State Budgetary Institution “Federal Scientifi c and Clinical Center for
Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency”
Russian Federation
Russian Federation
Sarmanaev Salavat Kh.
119435, Moscow
125371, Moscow
R. R. Tuktarova
City Clinical Hospital No. 21 Ufa
Russian Federation
Russian Federation
Tuktarova Rosa R.
450071, Ufa
Yu. O. Yurina
Academy of Postgraduate Education of the Federal State Budgetary Institution “Federal Scientifi c and Clinical Center for
Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency”
Russian Federation
Russian Federation
Yurina Yulia O.
125371, Moscow
References
1. Tu H., Tu S., Gao S., Shao A., Sheng J. Current epidemiological and clinical features of COVID-19; a global perspective from China. J. Infect. 2020;81(1):1–9. DOI: 10.1016/j.jinf.2020.04.011
2. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции COVID-19. Версия 17 (14.12.2022), МЗ РФ. -260 с.
3. Ge H., Wang X., Yuan X., Xiao G., Wang C., Deng T. et al. The epidemiology and clinical information about COVID-19. Eur. J. Clin. Microbiol. Infect. Dis. 2020;39(6):1011–9. DOI: 10.1007/s10096-020-03874-z
4. Ayalon I., Friedman S., Binenbaum Y., Oppenheimer N., Shiran S., Grisaru-Soen G. et al. A case of methotrexate neurotoxicity presented as status epilepticus, encephalopathy, and high fever. J. Investig. Med. High Impact Case Rep. 2019;7:2324709619862311. DOI: 10.1177/2324709619862311
5. Pannu A.K. Methotrexate overdose in clinical practice. Curr. Drug. Metab. 2019;20(9):714–9. DOI: 10.2174/1389200220666190806140844
6. Filatov A., Sharma P., Hindi F., Espinosa P.S. Neurological complications of coronavirus disease (COVID-19): encephalopathy. Cureus. 2020;12(3):e7352. DOI: 10.7759/cureus.7352
7. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5
8. Hedou M., Carsuzaa F., Chary E., Hainaut E., Cazenave-Roblot F., Masson Regnault M. Comment on ‘Cutaneous manifestations in COVID-19: a fi rst perspective’ by Recalcati S. J. Eur. Acad. Dermatol. Venereol. 2020;34(7):e299–e300. DOI: 10.1111/jdv.16387
9. Arif T., Dorner-Schulmeister S., Bartecka-Mino K. Oral methotrexate exposure: a 15-year survey of Austrian Poisons Information Centre cases. Clin. toxicology. 2018;56(6):490.
10. Sodnomova A.V. Finical case of complication of the rheumatoid arthritis therapy by methotrexate. Vestnik Buryatskogo gosudarstvennogo universiteta = Bull etin of the Buryat State University. 2013;(12):98–101. (In Russian.)].
11. Ivashkin V.T., Sheptulin A.A., Zolnikova O.Yu., Okhlobystin A.V., Poluektova E.A., Trukhmanov A.S. et al. New coronavirus infection (COVID-19) and digestive system. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(3):7–13 (In Russian)]. DOI: 10.22416/1382-4376-2020-30-3-7
12. Schulte-Güstenberg L. Intoxikationen durch Methotrexat. Eine retrospektive Analyse von 249 Fällen des Giftinformationszentrums-Nord. Inaugural-dissertation zur Erlangung des Doktorgrades der Medizinischen Fakultät der Georg-August-Universität zu Göttingen vorgelegt. Göttingen; 2019:85.
13. Bhojwani D., Sabin N.D., Pei D., Yang J.J., Khan R.B., Panetta J.C. et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2014;32(9):949–59. DOI: 10.1200/JCO.2013.53.0808
14. Howard S.C., McCormick J., Pui C.H., Buddington R.K., Harvey R.D. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–82. DOI: 10.1634/theoncologist.2015-0164
15. Perricone C., Triggianese P., Bartoloni E., Cafaro G., Bonifacio A.F., Bursi R. et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J. Autoimmun. 2020;111:102468. DOI: 10.1016/j.jaut.2020.102468
16. Ceribelli A., Motta F., De Santis M., Ansari A.A., Ridgway W.M., Gershwin M.E., Selmi C. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J. Autoimmun. 2020;109:102442. DOI: 10.1016/j.jaut.2020.102442
17. Sajith M., Pawar A., Bafna V., Bartakke S. High-dose methotrexate-induced fulminant hepatic failure and pancytopenia in an acute lymphoblastic leukaemia paediatric patient. Eur. J. Hosp. Pharm. 2020;27(3):178–80. DOI: 10.1136/ejhpharm-2019-001944
18. Cansu D.Ü., Teke H.Ü., Bodakçi E., Korkmaz C. How should we manage low-dose methotrexate-induced pancytopenia in patients with rheumatoid arthritis? Clin. Rheumatol. 2018;37(12):3419–25. DOI: 10.1007/s10067-018-4242-8
19. Pivovarov K., Zipursky J.S. Low-dose methotrexate toxicity. CMAJ. 2019;191(15):E423. DOI: 10.1503/cmaj.181054
20. Bubik R.J., Osmon D.R., Oravec C.P., Rivera C.G. Two cases of severe neutropenia in patients on low-dose methotrexate and ceftriaxone. Am. J. Health Syst. Pharm. 2019;76(11):804–9. DOI: 10.1093/ajhp/zxz057
21. Uy N., Thiagarajan P., Musher D.M. Cephalosporin side chain idiosyncrasies: a case report of ceftriaxone-induced agranulocytosis and review of literature. Open Forum Infect. Dis. 2015;2(1):ofv007. DOI: 10.1093/ofid/ofv007
22. Dittrich T., Marsch S., Egli A., Rüegg S., De Marchis G.M., Tschudin-Sutter S., Sutter R. Predictors of infectious meningitis or encephalitis: the yield of cerebrospinal fl uid in a cross-sectional study. BMC Infect. Dis. 2020;20(1):304. DOI: 10.1186/s12879-020-05022-6
23. Насонов Е.Л., Лила А.М., Мазуров В.И. и др. Ревматоидный артрит: клинические рекомендации. М. 2018:102.
24. Moriguchi T., Harii N., Goto J., Harada D., Sugawara H., Takamino J. et al. A fi rst case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int. J. Infect. Dis. 2020;94:55–8. DOI: 10.1016/j.ijid.2020.03.062
25. Schett G., Sticherling M., Neurath M.F. COVID-19: risk for cytokine targeting in chronic infl ammatory diseases? Nat. Rev. Immunol. 2020;20(5):271–2. DOI: 10.1038/s41577-020-0312-7
26. Haberman R., Axelrad J., Chen A., Castillo R., Yan D., Izmirly P. et al. COVID-19 in immune-mediated infl ammatory diseases – case series from New York. N. Engl. J. Med. 2020;383(1):85–8. DOI: 10.1056/NEJMc2009567
Review
For citations:
Zaborskikh I.V., Simonenko V.B., Sarmanaev S.Kh., Tuktarova R.R., Yurina Yu.O. Clinical case of methotrexate overdose, the peculiarity of diagnostics in the conditions of the COVID-19 pandemic. Clinical Medicine (Russian Journal). 2023;101(4-5):241-246. (In Russ.) https://doi.org/10.30629/0023-2149-2023-101-4-5-241-246
Views:
1436
Email this article 